自噬在失血性休克小鼠急性肺损伤中的生物学作用及相关机制
该研究将野生型雄性C57BL/6小鼠随机分为对照组、ALI组、雷帕霉素组和3-甲基腺嘌呤(3-MA)组,每组8只;并将C57BL/6背景的LC3基因敲除小鼠分为LC3敲除组和LC3敲除+ALI组,每组8只。对照组、ALI组、LC3敲除组、LC3敲除+ALI组腹腔注射2 mL/kg生理盐水,雷帕霉素组腹腔注射3 mg/kg自噬激活剂雷帕霉素,3-MA组腹腔注射15 mg/kg自噬抑制剂3-MA,均连续给药3天;末次给药后2小时建立失血性休克诱导的ALI模型,造模后24小时检测肺指数、肺损伤评分、LC3-II/LC3-I、Beclin-1及TNF-α、IL-6、MDA。结果显示,与ALI组相比,雷帕霉素组肺组织损伤减轻、肺指数和炎症氧化指标降低、自噬标志物升高(均P<0.05),3-MA组则损伤加重(均P<0.05);LC3敲除ALI小鼠的肺损伤和炎症氧化指标高于野生型ALI小鼠(均P<0.05)。作者认为自噬在失血性休克小鼠ALI中起保护作用,机制为抑制炎症反应和氧化应激反应。
要点
- 失血性休克ALI小鼠肺组织LC3-II/LC3-I和Beclin-1表达及TNF-α、IL-6、MDA含量均较对照组显著升高(均P<0.05)。
- 雷帕霉素组(3 mg/kg腹腔注射、连续3天)肺指数7.56±0.39% vs ALI组9.12±0.59%、肺损伤评分3.04±0.58 vs 9.32±2.14,均P<0.05。
- 雷帕霉素组TNF-α 1.85±0.32 ng/mg vs ALI组3.51±0.62 ng/mg、IL-6 1.61±0.32 ng/mg vs 2.52±0.44 ng/mg、MDA 1.03±0.16 nmol/mg vs 1.88±0.24 nmol/mg,均P<0.05。
- 3-MA组(15 mg/kg腹腔注射、连续3天)肺指数10.44±0.62% vs ALI组9.12±0.59%、肺损伤评分11.59±2.28 vs 9.32±2.14,均P<0.05。
- LC3敲除ALI小鼠肺指数10.44±0.75% vs 野生型ALI 9.12±0.59%、肺损伤评分12.41±2.86 vs 9.32±2.14,均P<0.05。
适用人群与场景
- 野生型雄性C57BL/6小鼠及C57BL/6背景LC3基因敲除小鼠,每组8只,用于失血性休克诱导的急性肺损伤模型。
处置流程与药物剂量
- 对照组、ALI组、LC3敲除组、LC3敲除+ALI组:腹腔注射2 mL/kg生理盐水,连续3天。
- 雷帕霉素组:腹腔注射3 mg/kg自噬激活剂雷帕霉素,连续3天。
- 3-MA组:腹腔注射15 mg/kg自噬抑制剂3-MA,连续3天。
- 末次给药后2小时建立失血性休克诱导的ALI模型,造模后24小时评估肺指数、肺损伤评分、自噬标志物及炎症氧化指标。
研究设计与关键结果
- 研究类型:小鼠实验;野生型雄性C57BL/6小鼠随机分为对照组、ALI组、雷帕霉素组、3-MA组,每组8只;LC3基因敲除小鼠分为LC3敲除组、LC3敲除+ALI组,每组8只。
- 与对照组比较,ALI组肺组织结构破坏、渗出增加,肺指数、肺损伤评分、LC3-II/LC3-I、Beclin-1及TNF-α、IL-6、MDA均显著升高。
- 与ALI组比较,雷帕霉素组肺组织结构损伤和渗出减轻,肺指数、肺损伤评分、TNF-α、IL-6、MDA降低,LC3-II/LC3-I和Beclin-1升高:肺指数(7.56±0.39)% vs (9.12±0.59)%、肺损伤评分3.04±0.58 vs 9.32±2.14、TNF-α(ng/mg)1.85±0.32 vs 3.51±0.62、IL-6(ng/mg)1.61±0.32 vs 2.52±0.44、MDA(nmol/mg)1.03±0.16 vs 1.88±0.24、LC3-II/LC3-I 1.21±0.12 vs 0.39±0.05、Beclin-1/β-actin 1.10±0.12 vs 0.58±0.06,均P<0.05。
- 与ALI组比较,3-MA组肺组织结构损伤加重、渗出进一步增加,肺指数、肺损伤评分、TNF-α、IL-6、MDA升高,LC3-II/LC3-I和Beclin-1降低:肺指数(10.44±0.62)% vs (9.12±0.59)%、肺损伤评分11.59±2.28 vs 9.32±2.14、TNF-α(ng/mg)4.77±0.71 vs 3.51±0.62、IL-6(ng/mg)3.44±0.52 vs 2.52±0.44、MDA(nmol/mg)2.71±0.42 vs 1.88±0.24、LC3-II/LC3-I 0.25±0.04 vs 0.39±0.05、Beclin-1/β-actin 0.21±0.03 vs 0.58±0.06,均P<0.05。
- LC3敲除ALI小鼠肺指数、肺损伤评分、TNF-α、IL-6、MDA均高于野生型ALI小鼠:肺指数(10.44±0.75)% vs (9.12±0.59)%、肺损伤评分12.41±2.86 vs 9.32±2.14、TNF-α(ng/mg)4.85±0.72 vs 3.51±0.62、IL-6(ng/mg)3.28±0.51 vs 2.52±0.44、MDA(nmol/mg)2.75±0.41 vs 1.88±0.24,均P<0.05。
证据类型、等级与局限
- 证据类型:小鼠实验(动物实验)。
- 作者结论:自噬在失血性休克小鼠急性肺损伤中起保护作用,相关分子机制为抑制炎症反应和氧化应激反应。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为小鼠实验,未据此给出临床推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To study the biological role and related mechanism of autophagy in acute lung injury (ALI) of hemorrhagic shock mice.
METHODS: According to random number table method, wild-type male C57BL/6 mice were divided into control group, ALI group, rapamycin group and 3-methyladenine (3-MA) group, with 8 mice in each group. Light chain 3 (LC3) gene knockout mice with C57BL/6 background were divided into LC3 knockout group and LC3 knockout+ALI group, with 8 mice in each group. Control group, ALI group, LC3 knockout group, LC3 knockout+ALI group were intraperitoneally injected with 2 mL/kg normal saline, rapamycin group was intraperitoneally injected with 3 mg/kg autophagy activator rapamycin, 3-MA group was intraperitoneally injected with 15 mg/kg autophagy inhibitor 3-MA, all of which were given for 3 consecutive days. 2 hours after the last administration, the hemorrhagic shock induced ALI model was established. 24 hours after modeling, the lung index was calculated. Hematoxylin-eosin (HE) staining was used to observe the pathological changes of lung tissue and lung injury score was performed. The expressions of autophagy genes LC3- II/LC3- I and Beclin-1 in lung tissue were detected by Western blotting. The contents of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA) in lung tissue were detected according to the steps of the kit.
RESULTS: Compared with the control group, the lung tissue structure was destroyed and exudation increased, lung index, lung injury score, the expressions of LC3- II/LC3- I, Beclin-1, and the contents of TNF-α, IL-6 and MDA in lung tissue significantly increased in the ALI group. Compared with the ALI group, the structural damage and exudation of lung tissue were reduced in the rapamycin group, lung index, lung injury score and the contents of TNF-α, IL-6 and MDA in lung tissue decreased, while the expressions of LC3- II/LC3- I and Beclin-1 in lung tissue increased [lung index: (7.56±0.39)% vs. (9.12±0.59)%, lung injury score: 3.04±0.58 vs. 9.32±2.14, TNF-α (ng/mg): 1.85±0.32 vs. 3.51±0.62, IL-6 (ng/mg): 1.61±0.32 vs. 2.52±0.44, MDA (nmol/mg): 1.03±0.16 vs. 1.88±0.24, LC3- II/LC3- I: 1.21±0.12 vs. 0.39±0.05, Beclin-1/β-actin: 1.10±0.12 vs. 0.58±0.06, all P < 0.05], while lung tissue structure damage was aggravated and exudation was further increased in the 3-MA group, lung index, lung injury score and the contents of TNF-α, IL-6 and MDA in lung tissue increased, the expressions of LC3- II/LC3- I and Beclin-1 in lung tissue decreased [lung index: (10.44±0.62)% vs. (9.12±0.59)%, lung injury score: 11.59±2.28 vs. 9.32±2.14, TNF-α (ng/mg): 4.77±0.71 vs. 3.51±0.62, IL-6 (ng/mg): 3.44±0.52 vs. 2.52±0.44, MDA (nmol/mg): 2.71±0.42 vs. 1.88±0.24, LC3- II/LC3- I: 0.25±0.04 vs. 0.39±0.05, Beclin-1/β-actin: 0.21±0.03 vs. 0.58±0.06, all P < 0.05]. Lung index, lung injury score and the contents of TNF-α, IL-6 and MDA in lung tissue of LC3 knockout ALI mice were higher than those of wild-type ALI mice [lung index: (10.44±0.75)% vs. (9.12±0.59)%, lung injury score: 12.41±2.86 vs. 9.32±2.14, TNF-α (ng/mg): 4.85±0.72 vs. 3.51±0.62, IL-6 (ng/mg): 3.28±0.51 vs. 2.52±0.44, MDA (nmol/mg): 2.75±0.41 vs. 1.88±0.24, all P < 0.05].
CONCLUSIONS: Autophagy plays a protective role in ALI of hemorrhagic shock mice, and the related molecular mechanism is the inhibition of inflammatory response and oxidative stress response.
参考来源
- Lin X, Wang J, Zhang Z, et al. [Biological role and related mechanism of autophagy in acute lung injury of hemorrhagic shock mice]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 39238409. doi:10.3760/cma.j.cn121430-20231007-00844
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。